Deals, Dupixent and GLP-1 drug shortages

FromBioSpace

Start listening View podcast show

Deals, Dupixent and GLP-1 drug shortages

FromBioSpace

ratings:

Length:

17 minutes

Released:

Nov 29, 2023

Format:

Podcast episode

Description

This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠Dupixent⁠⁠ in COPD.
Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship.
Join BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss the most important biopharma news this week.

Released:

Nov 29, 2023

Format:

Podcast episode

Titles in the series (46)

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Skip carousel

Q3 earnings recap: winners, losers & surprises by BioSpace
18 min listen
Zepbound vs Wegovy: a two horse race by BioSpace
14 min listen
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure by BioSpace
18 min listen
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA by BioSpace
21 min listen
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety by BioSpace
17 min listen
Deals, Dupixent and GLP-1 drug shortages by BioSpace
17 min listen
The top life sciences startups to watch this year by BioSpace
15 min listen
Fast and furious evolution: how to ensure AI is catalyst for positive societal change with Microsoft and IQVIA by BioSpace
32 min listen
First ever CRISPR gene therapy approval: What happens next? by BioSpace
13 min listen
GLP-1 and ADC rollercoasters pick up speed by BioSpace
13 min listen
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior by BioSpace
17 min listen
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
45 min listen
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny by BioSpace
17 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics by BioSpace
48 min listen
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
22 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
Grab an umbrella, it's raining ⁠IPOs⁠! by BioSpace
11 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
Every move you make: biopharma industry under heavy scrutiny by BioSpace
16 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The skinny on weight loss, donanemab and the State of the Union by BioSpace
16 min listen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now by BioSpace
11 min listen

More Episodes from BioSpace

Skip carousel

Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap by BioSpace
15 min listen
Women's Health: Where Politics and Science Meet by BioSpace
22 min listen
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird by BioSpace
12 min listen
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy by BioSpace
12 min listen
The IRA, BMS’ Big Cuts, First WHIM Approval by BioSpace
16 min listen
Where Do We Go From Here? The Future of Women's Health by BioSpace
22 min listen
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player by BioSpace
18 min listen
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages by BioSpace
20 min listen
It's a Design Problem: Women and Clinical Trials by BioSpace
20 min listen
Alphabet Soup: AACR and ACC Dominate Headlines This Week by BioSpace
17 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients? by BioSpace
22 min listen
Bayer’s sweeping executive cuts, Wegovy’s expanding reach by BioSpace
17 min listen
Money talk: Salary trends and raises by BioSpace
15 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The unintended consequences of small molecules by BioSpace
25 min listen
The skinny on weight loss, donanemab and the State of the Union by BioSpace
16 min listen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now by BioSpace
11 min listen
The gap is where the pain is: Drug pricing and patient costs by BioSpace
20 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen
Balancing act: Patient access and innovation by BioSpace
21 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Grab an umbrella, it's raining ⁠IPOs⁠! by BioSpace
11 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen

Related podcast episodes

Skip carousel

Zepbound (Tirzepatide for obesity) receives FDA-Approval! by The Gaining Health Podcast
16 min listen
The Way of Wegovy Part 2: Obesity Treatment and New Frontiers by Beyond the Abstract
23 min listen
Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma by Beyond Biotech - the podcast from Labiotech
46 min listen
More Positive Data for Tirzepatide Weight Loss Injection + Sandoz's Global Biosimilars Awareness Campaign by Xtalks Life Science Podcast
23 min listen
Why Are CPG Brands Freaking Out About Ozempic?: This week SuperGut CEO Marc Washington joins the podcast to talk about why new GLP-1 drugs like Ozempic and Wegovy are keeping CPG brand CEOs up at night. These new drugs, which got their start as a new class of pharmaceuticals that help contol type 2... by The Spoon Podcast
31 min listen
The Game Changer by OIS Podcast | Ophthalmology's leading Podcast
55 min listen
Pamela Kaufman: Anti-Obesity Meds Could Bite Into Food Sales by Thoughts on the Market
4 min listen
GLP-1s may save healthcare billions but could cost companies growth and revenues: GLP-1 impact should be big but lots of puts and takes Almost 40% of US adults are obese and the US healthcare system spends nearly $173 billion a year on obesity-related medical costs. In the past, exercise and diet regiments were the best solutions ... by Global Research Unlocked
22 min listen
Pharmacotherapies for Post-Bariatric Weight Regain by The Gaining Health Podcast
8 min listen
Can Ozempic Fix Our Obesity Crisis? by The Doctor's Farmacy with Mark Hyman, M.D.
52 min listen
GLP-1 Medications with Dr. Isabelle Amigues: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are all the rage right now. Originally marketed as drugs to help diabetics with insulin resistance, they were later discovered to help people lose weight. With those possibilities, GLP-1 meds are... by Fibromyalgia Podcast®
37 min listen
Buh-Bye Food Noise with Dr. Spencer of WeightWatchers by Taste of Taylor
59 min listen
Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity: Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast
65 min listen
Should YouTake A Weight Loss Drug?: Dr Barbara Mintzes and Dr Joel Lexchin, have recently published a paper on the weight loss drug Wegovy (generic name semaglutide). They discuss it and the new generation of similar obesity medications. The hype surrounding this new class of drugs has... by What Your GP Doesn’t Tell You
50 min listen
GLP-1 Weight Loss Drugs in Patients With Bipolar Disorder or Eating Disorders: Two articles in the March-April 2024 issue of the Journal of Clinical Psychopharmacology present research on glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications that has drawn considerable media attention in... by The Journal of Clinical Psychopharmacology Podcast
13 min listen
Stephan Guyenet, PhD: GLP-1, Semaglutide, and the Big Future of Weight Loss Therapies by The External Medicine Podcast
65 min listen
Stocks Close Out A Big First Quarter… And The True Cost Of Diabetes Drugs 3/28/24: Q1 is in the books, and stocks are heading into Q2 with some major accomplishments. Can the market rally keep raging? And where you should be positioned going into the second quarter. Plus… what it really costs to craft these diabetes drugs. A new study pointing to a $5 price tag for a month’s worth of one blockbuster GLP-1 drug. The dollar dichotemy… and if prices will come down for the public. Fast Money Disclaimer by CNBC's "Fast Money"
44 min listen
Here's How the New Weight Loss Drugs Could Change Everything by Odd Lots
55 min listen
A Journey Through Top Articles of 2023 with Dr. Matthew Greenhot by The Allergist
38 min listen
Zepbound vs Wegovy: a two horse race by BioSpace
14 min listen
Beyond Biotech podcast 27: Cradle, Rani Therapeutics by Beyond Biotech - the podcast from Labiotech
39 min listen
How Weight-Loss Drugs Could Impact U.S. Healthcare and Food. Plus, the Biggest Problems With GLP1s. by Plain English with Derek Thompson
92 min listen
Pharmaceuticals: The Investment Opportunity in Obesity Treatment by Thoughts on the Market
7 min listen
140: Lipedema: Keto Is Part Of The Cure by Dr Karl Goldkamp - Keto Naturopath
40 min listen
December 1 2009 Issue: A short-term randomized MRI study of high-dose oral vs. intravenous methyprednisolone in MS by Neurology® Podcast
21 min listen
Adam Feuerstein talks COVID-19 treatments and vaccines on Alpha Trader by Alpha Trader
28 min listen
LLAMA LIVE! Longevity lessons from Covid-19 by Live Long and Master Aging
32 min listen
Eli Lilly to Develop RNA Editing Therapies + Study Shows Benefits of Daily Steps by Xtalks Life Science Podcast
24 min listen
EULAR 2021 - Day2a: Serious Infection Risk from the Filgotinib Drug Development Program_ Dr. James Galloway Spacing Anti-TIF Inhibitors for Axial SpA_ Dr. Eric Dein The Future of Treatment of RA-ILD_ Dr. David Liew Three New Medications for Lupus_ Dr. Eric Dein Treatment Op... by Rheumnow Podcast
38 min listen
GLP-1 Use & Muscle Loss by DocTalk with Dr. Adam Nally
11 min listen

Discover this podcast and so much more

Deals, Dupixent and GLP-1 drug shortages

Deals, Dupixent and GLP-1 drug shortages

Description

Titles in the series (46)

More Episodes from BioSpace

Related podcast episodes